Nucs AI applies computer vision and deep learning to prostate cancer diagnostics, built on a modern web stack (React, TypeScript, FastAPI, Kubernetes, GCP). The tech foundation—WebGL/WebGPU for client-side rendering, RabbitMQ for async workflows, and SQL/Kubernetes for backend scale—reflects a medical-imaging SaaS designed to move analysis from radiologist workstations into cloud infrastructure. Early-stage hiring skews toward healthcare and leadership roles (sales director, partnership director), suggesting a clinical go-to-market strategy paired with scaling validation infrastructure.
Notable leadership hires: Sales Director, Partnership Director
Nucs AI develops an AI platform for analyzing prostate cancer imaging, targeting radiologists and oncology teams. Founded in 2024 and based in San Francisco, the 11–50-person company focuses on automated tumor lesion assessment and personalized treatment planning. The product combines medical image processing (DICOM data architecture, 3D visualization) with model inference and clinical annotation workflows. Active projects span the imaging pipeline (model training, advanced visualization frontends) and clinician engagement (KOL partnerships, scientific publications), indicating a product roadmap that bridges technical capability with clinical adoption.
React, TypeScript, FastAPI, Python, SQL, Kubernetes, RabbitMQ, and GCP. WebGL and WebGPU power client-side medical image rendering; FastAPI handles backend inference.
San Francisco, California. The company is also hiring in Germany, indicating early international expansion.
Other companies in the same industry, closest in size